CRBU FY2029 EPS Decreased by Brookline Capital Management

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Research analysts at Brookline Capital Management dropped their FY2029 earnings estimates for shares of Caribou Biosciences in a research report issued on Tuesday, March 11th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings of $16.83 per share for the year, down from their previous estimate of $16.92. The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share.

A number of other brokerages also recently weighed in on CRBU. Citigroup lowered their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a "buy" rating for the company in a research report on Tuesday, November 26th. Bank of America decreased their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $10.33.

Caribou Biosciences Price Performance

Shares of NASDAQ:CRBU traded up $0.02 during trading on Wednesday, reaching $1.01. 739,253 shares of the company's stock traded hands, compared to its average volume of 1,609,452. Caribou Biosciences has a 12 month low of $0.98 and a 12 month high of $5.77. The company has a 50 day moving average of $1.37 and a 200-day moving average of $1.77. The stock has a market capitalization of $93.94 million, a P/E ratio of -0.61 and a beta of 2.34.

Remove Ads

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its earnings results on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.01. The company had revenue of $2.08 million during the quarter, compared to the consensus estimate of $2.11 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%.

Institutional Trading of Caribou Biosciences

A number of institutional investors have recently made changes to their positions in the stock. Ancora Advisors LLC lifted its stake in shares of Caribou Biosciences by 16.0% in the 4th quarter. Ancora Advisors LLC now owns 58,000 shares of the company's stock worth $92,000 after acquiring an additional 8,000 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Caribou Biosciences by 28.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 35,848 shares of the company's stock valued at $57,000 after purchasing an additional 8,008 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Caribou Biosciences by 4.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 176,654 shares of the company's stock valued at $281,000 after purchasing an additional 8,199 shares during the last quarter. Milestone Asset Management LLC lifted its stake in Caribou Biosciences by 5.6% during the fourth quarter. Milestone Asset Management LLC now owns 163,789 shares of the company's stock valued at $260,000 after purchasing an additional 8,662 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its stake in Caribou Biosciences by 60.0% during the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock valued at $39,000 after purchasing an additional 9,148 shares during the last quarter. 77.51% of the stock is owned by institutional investors and hedge funds.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.